Clinical Trials
- Pancreatic Cancer
The Cancer of the Pancreas Screening-5 (CAPS5) Study
- Ages18 years and older
- GenderBoth
- Pancreatic Cancer
A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Patients With Resected Pancreatic Ductal Adenocarcinoma
- Colorectal Cancer, Sarcoma Cancers, Stomach and Esophagus, Kidney Cancer, Head and Neck Cancers, Liver Cancer, Lung Cancer, Gynecological Cancers, Pancreatic Cancer, Prostate Cancer, Thyroid and Other Endocrine Cancers, Breast Cancer
PROgram to address psychosocial Support, clinical outcomes, and genomic insights for Patients with EaRly onset cancers
- Children's Health, Genetics
Pediatric Genomics Discovery Program (PGDP)
- GenderBoth
- Phase 1 Cancers
A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Advanced Solid Tumors Harboring a p53 Y220C Mutation (PYNNACLE)
- Phase 1 Cancers
A Phase 1a/1b Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors
- Phase 1 Cancers
A Phase 1 Trial Evaluating the Safety, Tolerability, PK, and Efficacy of QTX3034 in Patients With Solid Tumors With KRASG12D Mutation
- Phase 1 Cancers
A Phase 1/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and anti-tumor activity of PF-07220060 as a Single Agent and as Part of Combination Therapy in Participants with Advanced Solid tumors (WIRB)
- Phase 1 Cancers
A Phase 1, Open-Label Dose Escalation and Expansion Study of SNV1521 in Participants With Advanced Solid Tumors
- Phase 1 Cancers
A Phase 1 Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, and Anti-tumor Activity of PF-07248144 in Participants With Advanced or Metastatic Solid Tumors